Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

for the first nine months of fiscal 2007 were $2.4 million compared to $1.8 million for the first nine months of fiscal 2006.

Selling, general and administrative costs for the first nine months of fiscal 2007 increased to $16.0 million from $11.1 million for the first nine months of fiscal 2006. The rationale for the increase is consistent with that for the third quarter and also includes an increase in non-cash stock-based compensation expense of $1.3 million.

Net loss for the first nine months of fiscal 2007 was $26.5 million, or $0.47 per share, compared to $16.7 million, or $0.33 per share for the first nine months of fiscal 2006.

Labopharm continues to expect global sales of its once-daily tramadol product to be variable from quarter to quarter as a result of pipeline fill and other supply chain and market dynamics associated with the early stages of product launches. Labopharm believes that the continued penetration of markets in which its product has already been launched, as well as additional product launches globally, will result in quarter over quarter growth in product sales.

Conference Call

Labopharm will host a conference call today (Friday, November 9, 2007 at 8:30 a.m. ET) to discuss its third quarter fiscal 2007 results. To access the conference call by telephone, dial (416) 644-3427 or 1-800-589-8577. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 16, 2007 at midnight. To access the archived conference call, dial (416) 640-1917 or 1-877-289-8525 and enter the reservation number 21251082 followed by the number sign. A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to jo
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...h holds open house at Victoria campus , ...09 -- UCW Academy of Health invites anyone looking...lth care industry to attend their open house in Vi...ademy of Health, which offers diplomas in areas su... designs its programs to meet the needs of the hea...
(Date:11/8/2009)...e/ -- Speaker Nancy Pelosi and Democratic leaders ...e of H.R. 3962, the Affordable Health Care for Ame.... Below are the Speaker,s opening remarks: ,,... from the President of the United States, Barack O... American people. I thank the President for his tr...
(Date:11/8/2009)...is pleased to announce that it has been successful...nd who recently received an award on the $800 mill...ludes not only the Veterans Administration, but al...ncies. , New York, NY (PR...eased to announce that it has been successful in p...
(Date:11/8/2009)...n the Western District of Pennsylvania award a Fay... for a medical malpractice case. Attorneys Thomas...s E. Crenney and Associates, LLC handled the case ...gainst the Uniontown Hospital. The woman had to h...ge 18. , Pittsburgh, PA(P...
(Date:11/8/2009)...alth advocates committed to achieving meaningful h...7 "Tonight the U.S. Hou...oice of America,s families by passing the Affordab...t deliver, without delay, on the promise of meanin..., President and CEO of the National Alliance for H...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
...e,s Closure to Have Disproportionate Impact On Lat...rved Groups, OAKLAND, Calif., Oct. 25 Sutter Hea...n Francisco will have a particularly,adverse impac...tee. CNA/NNOC presented the data at a San Francisc...
...new way to treat individuals with cancer that is b...nd kill cancer cells while leaving normal cells un...s. In a new study, David Kirn and colleagues at Je...er selecting a highly potent strain of poxvirus th...
...ADELPHIA A new Center for Excellence in Ethical, ...been established at the University of Pennsylvania...ols of Nursing and Arts and Sciences, the Wharton ...over $5 million over the next five years from the ...
...ue allows trapped air a way out, experts say , THU...o treat emphysema patients shows promise, research...uctive pulmonary disease (COPD), is a progressive,...s a minimally invasive, catheter-based bronchoscop...
...ER, Oct. 25 /PRNewswire-FirstCall/ - Biotech Holdi... it has signed an agreement, with,a private compan...ion of,its Sucanon Type II diabetes drug in four C...l population of approximately 33 million people, w...
...IL, Oct. 25 /PRNewswire-FirstCall/ - SXC Health So...that Mr. Gordon S. Glenn, Chairman and,Chief Execu...day, November,8, 2007 at 8:30 a.m. ET to discuss t...y. All interested parties can join the call by di...
Other Medicine News:Health News:CNA Presents New Data on Sutter's Medical Redlining 2Health News:CNA Presents New Data on Sutter's Medical Redlining 3Health News:Penn wins $5M to start center for ethical, legal and social implications research 2Health News:Penn wins $5M to start center for ethical, legal and social implications research 3Health News:SXC Health Solutions to Host Fiscal 2007 Third Quarter Financial Results Conference Call 2
(Date:11/6/2009)...,, OAKLAND, Calif., Nov. 6 Kais... Hospitals (KFHP/H), and their subsidiaries report....5 billion for the quarter ended September 30, 200...of last year. Operating income in the third quarte...e third quarter of last year. Net non-operating in...
(Date:11/6/2009)...,, CHARLESTON, S.C., Nov. 6 /PRNewswire-USNew... be stopping in South Carolina and Georgia through... order to help uninsured and financially-strugglin...vide prescription medicines for free or nearly fre... 10.2 percent, the Partnership for Prescription As...
(Date:11/6/2009)...,, SAN DIEGO, Nov. 6 ...company focused on developing products for minimal...nnounced today the appointment of Michael J. Lambe... Officer, effective November 9, 2009. The Company... Team updates. ,, "Michael will be an excellent...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 1Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 2Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 3Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 4Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 5Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 6Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 7Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 8PracticeMatch Announces Departure From Physician Recruiting 53526 1PracticeMatch Announces Departure From Physician Recruiting 53526 2Operation Rescue Announces Keep It Closed Campaign 53523 1Operation Rescue Announces Keep It Closed Campaign 53523 2
...hering-Plough,Corporation (NYSE: SGP ) today repo...senapine, a fast-dissolving, sublingual tablet bei...ore effective than placebo,and well tolerated in t...ding to the results, asenapine 5 mg twice daily an...ffective than placebo at improving,patient Positiv...
...SuperGen, Inc.,(Nasdaq: SUPG ) today announced th... multi-arm Phase 1b clinical trial of MP470, a nov...(TKI). The trial will evaluate,MP470 in combinatio...ens,including carboplatin/paclitaxel, carboplatin/... trial is expected to enroll up to 105,patients at...
Other Medicine Technology:New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor 2SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor 3
...medium designed for the direct detection and/or co...ted for the suppression of gram-negative organisms...eus hydrolyzes the chromogenic substrate resulting...n from other gram-positive organisms. A cephalospo...
Autoclavable Light Guides & Adapters
...h a 180 watt Xenon short arc lamp. Designed to pro... transfer from the lamp to the light guide, this l...alent to higher watt bulbs. A new IR filtering sys...mount of heat generated from the light source and ...
... your video equipment has led Linvatec to develop ...odate all of your multi-specialty video requiremen...ers in both traditional eyecup and proprietary fog...oom "C mount eyecup and both "C and "V mount eyecu...
Medicine Products: